Charles Schwab Investment Management Inc. raised its position in Smith & Nephew plc (NYSE:SNN – Free Report) by 29.3% in the third quarter, Holdings Channel reports. The institutional investor owned 27,199 shares of the medical equipment provider’s stock after purchasing an additional 6,164 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Smith & Nephew were worth $847,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Pathstone Holdings LLC raised its holdings in shares of Smith & Nephew by 14.8% during the third quarter. Pathstone Holdings LLC now owns 48,903 shares of the medical equipment provider’s stock valued at $1,523,000 after acquiring an additional 6,317 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its position in shares of Smith & Nephew by 5.6% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 17,218 shares of the medical equipment provider’s stock valued at $536,000 after acquiring an additional 920 shares during the last quarter. Ashton Thomas Securities LLC grew its stake in shares of Smith & Nephew by 8.4% in the 3rd quarter. Ashton Thomas Securities LLC now owns 69,849 shares of the medical equipment provider’s stock valued at $2,175,000 after buying an additional 5,385 shares during the period. Crossmark Global Holdings Inc. increased its position in shares of Smith & Nephew by 63.7% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 112,859 shares of the medical equipment provider’s stock worth $3,515,000 after purchasing an additional 43,924 shares during the last quarter. Finally, River Road Asset Management LLC acquired a new stake in Smith & Nephew in the 3rd quarter valued at approximately $38,588,000. Hedge funds and other institutional investors own 25.64% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on SNN. StockNews.com cut Smith & Nephew from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Berenberg Bank cut Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Wednesday, November 6th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of Smith & Nephew from a “buy” rating to a “hold” rating in a research note on Friday, November 1st.
Smith & Nephew Stock Performance
Shares of Smith & Nephew stock opened at $24.89 on Thursday. The firm’s 50 day moving average is $26.36 and its two-hundred day moving average is $27.90. Smith & Nephew plc has a 52 week low of $23.65 and a 52 week high of $31.72. The company has a quick ratio of 1.11, a current ratio of 2.51 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $10.88 billion, a P/E ratio of 12.70, a P/E/G ratio of 1.41 and a beta of 0.84.
Smith & Nephew Company Profile
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Further Reading
- Five stocks we like better than Smith & Nephew
- What is the Euro STOXX 50 Index?
- Novo Nordisk: A New Boost for GLP-1 Sales on the Horizon
- Pros And Cons Of Monthly Dividend Stocks
- Why Now Is the Ultimate Time to Invest in Oil Stocks
- Stock Analyst Ratings and Canadian Analyst Ratings
- Q4’s Most Upgraded Stocks: Promising Buys for 2025
Want to see what other hedge funds are holding SNN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Smith & Nephew plc (NYSE:SNN – Free Report).
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.